Skip to main content
Premium Trial:

Request an Annual Quote

Myriad's Investment in RainDance Totals $5M

NEW YORK (GenomeWeb News) – Myriad Genetics' investment into RainDance Technologies totals $5.0 million, the Salt Lake City-based company said in its Form 10-Q filed with the US Securities and Exchange Commission this week.

RainDance announced last week the closing of a $20 million Series E financing round, saying Myriad had joined as a strategic equity investor. In its SEC document, Myriad said that it acquired about 28 million shares of RainDance's Series E preferred stock as part of its investment.

It added that the "Series E shares represent less than 5 percent of the total shares outstanding of RainDance's capital stock."

Earlier last month, Myriad and RainDance also announced a multiyear deal for the adoption of RainDance's microdroplet PCR-based target enrichment technology.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.